Aligos Therapeutics Inc (ALGS)

Aligos Therapeutics Inc Azioni (ALGS) Dati Finanziari

Conto economico

Trimestrale

*Tutti i numeri sono espressi in milioni

Data di fine periodo	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31
Durata del periodo	3 mesi	3 mesi	3 mesi	3 mesi	3 mesi
Revenues	3.27% 0.694	0.672	1.085	4.294	0.14
Operating Expenses	19.69% 23.03	28.68	22.31	26.03	26.64
Benefits Costs and Expenses	24.27% 35.53	28.59	19.10	22.33	23.06
Costs And Expenses	24.27% 35.53	28.59	19.10	22.33	23.06
Provision For Loan, Lease, And Other Losses	-	-	-	-	-
Operating Income/Loss	15.20% -22.05	-26.00	-19.07	-19.14	-23.92
Net Interest Income/Expense	0.60	-	-	-	-
Interest Income/Expense After Provision For Losses	0.60	-	-	-	-
Income/Loss From Continuing Operations Before Tax	24.77% -34.84	-27.92	-18.01	-18.03	-22.92
Income Tax Expense/Benefit	180.00% 0.024	-0.03	0.029	0.757	0.039
Income/Loss From Continuing Operations After Tax	24.99% -34.86	-27.89	-18.04	-18.79	-22.95
Net Income/Loss	24.99% -34.86	-27.89	-18.04	-18.79	-22.95
Preferred Stock Dividends And Other Adjustments	-	-	-	-	-
Attributable To Noncontrolling Interest	-	-	-	-	-
Basic Average Shares	641.79% 156.15	21.05	43.50	43.22	42.91
Diluted Average Shares	641.79% 156.15	21.05	43.50	43.22	42.91
Basic Earnings Per Share	1,200% -0.22	0.02	-0.41	-0.43	-0.53
Diluted Earnings Per Share	1,200% -0.22	0.02	-0.41	-0.43	-0.53
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic	-	-	-	-	-